Kyverna Therapeutics, Inc. Common Stock KYTX
i
Market datapartial · fetched 2026-11-12T03:16:05.758Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T23:37:57.175169272Z
FundamentalsAlpha Vantage · unavailable
Kyverna Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | 5.25 | 135.0% | 17.5% | |||
| 45Δ | 5.80 | 138.6% | 15.8% | |||
| 50Δ | 6.35 | 142.2% | 14.1% | |||
| 55Δ | 6.90 | 145.8% | 12.4% | |||
| 60Δ | 5.19 | 158.2% | 20.5% | 7.44 | 149.4% | 10.7% |
| 65Δ | 7.99 | 153.0% | 9.1% | |||
| 70Δ | 8.54 | 156.7% | 7.4% | |||
| 75Δ | 9.09 | 160.3% | 5.7% | |||
| 80Δ | 9.64 | 163.9% | 4.0% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.25
- IV
- 135.0%
- B/E move
- 17.5%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.80
- IV
- 138.6%
- B/E move
- 15.8%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.35
- IV
- 142.2%
- B/E move
- 14.1%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.90
- IV
- 145.8%
- B/E move
- 12.4%
60Δ
- Pseudo strike
- 5.19
- IV
- 158.2%
- B/E move
- 20.5%
- Pseudo strike
- 7.44
- IV
- 149.4%
- B/E move
- 10.7%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.99
- IV
- 153.0%
- B/E move
- 9.1%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.54
- IV
- 156.7%
- B/E move
- 7.4%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.09
- IV
- 160.3%
- B/E move
- 5.7%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.64
- IV
- 163.9%
- B/E move
- 4.0%
Options history
Table
| Date | IV (%) |
|---|---|
| 177.57% |
Biotechnology
KZIA
Kazia Therapeutics Limited, a biotechnology company focused on oncology, develops anticancer drugs. The company is headquartered in Sydney, Australia.
More →LBRX
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.…
More →LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the…
More →LEGN
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in…
More →LENZ
LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders, specifically targeting critical…
More →LGND
Description unavailable
More →